Invivyd 주식 가격. IVVD - 주식 시세, 차트, 과거 거래, 주식 채팅, 재무.

포트폴리오 강화: 실시간 토론 및 실행 가능한 거래 아이디어.

프리미엄

가격

0.429

매수가

0.405

매도가

0.429

거래량

760,459

0.4002 일간 변동폭 0.4471

0.382 52주 범위 5.195

market_cap

51.315M

전일 종가

0.4393

개장가

0.4395

최근 거래 시간

400

0.429

(formt)

마지막 거래 시간

재정 규모

US$ 315,386

VWAP

0.414731

평균 볼륨(3m)

1,110,245

발행 주식

119,616,035

배당수익률

주가수익률

-2.79

주당순이익(EPS)

-1.66

매출

순이익

-198.64M

Invivyd Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and ... Invivyd Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's lead product candidate, ADG20 is developed for the treatment and prevention of coronavirus disease which has demonstrated clinically meaningful results in global Phase 3 clinical trials against multiple variants of concern for the prevention and treatment of COVID-19. 더 보기

섹터

Biological Pds,ex Diagnstics

산업

Biological Pds,ex Diagnstics

웹사이트

invivyd.com

본부

Wilmington, Delaware, USA

설립됨

Invivyd Inc is listed in the Biological Pds,ex Diagnstics sector of the 나스닥 with ticker IVVD. The last closing price for Invivyd was US$0.44. Over the last year, Invivyd shares have traded in a share price range of US$ 0.382 to US$ 5.195.

Invivyd currently has 119,616,035 shares in issue. The market capitalisation of Invivyd is US$52.55 million. Invivyd has a price to earnings ratio (PE ratio) of -2.79.

Form 8-K - Current report

Invivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Dominant SARS-CoV-2 Variant XEC

New in vitro neutralization data show continued, consistent neutralizing activity of PEMGARDA™ (pemivibart) against XEC Centers for Disease Control reports XEC and KP.3.1.1 (previously disclosed...

Form 8-K - Current report

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Invivyd Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Q3 2024 PEMGARDA™ (pemivibart) net product revenue of $9.3 million; Invivyd ended Q3 2024 with $106.9 million in cash and cash equivalentsTargets near-term (1H 2025) profitability with existing...

Invivyd Announces New England Journal of Medicine Publishes Letter to the Editor Highlighting Immunobridging Pathway Leading to PEMGARDA™ (pemivibart) Emergency Use Authorization; Comments on Adjacent Third-Party Letter to the Editor

The New England Journal of Medicine (NEJM) Letter to the Editor outlines the novel, rapid immunobridging authorization pathway for PEMGARDA and provides an updated correlate of protection curve...

Invivyd Announces Preprints Conveying CANOPY Phase 3 Clinical Trial Data Including Long-Term Protection Versus Recent JN.1 Sublineages at Low Residual Titers, and Describing a Novel Approach for Predicting Monoclonal Antibody Activity Were Uploaded to MedR

CANOPY manuscript preprint includes six-month off-drug follow-up period that highlighted strong protection by pemivibart versus placebo in the immunocompetent Cohort B during KP.3 and KP.3.1.1...

기간	변동	변동 %	시가	고가	저가	평균 일일 거래량	VWAP
1	-0.0311	-6.75940013041	0.4601	0.5	0.382	3741060	0.44040094	CS
4	0.009	2.14285714286	0.42	0.59	0.382	1966556	0.46155636	CS
12	-0.581	-57.5247524752	1.01	1.07	0.382	1110245	0.57050325	CS
26	-0.911	-67.9850746269	1.34	1.455	0.382	735088	0.72311454	CS
52	-3.471	-89	3.9	5.195	0.382	712693	1.92822531	CS
156	-4.271	-90.8723404255	4.7	5.195	0.382	589462	2.330886	CS
260	-4.271	-90.8723404255	4.7	5.195	0.382	589462	2.330886	CS

IVVD - Frequently Asked Questions (FAQ)

What is the current Invivyd share price?

The current share price of Invivyd is US$ 0.429

How many Invivyd shares are in issue?

Invivyd has 119,616,035 shares in issue

What is the market cap of Invivyd?

The market capitalisation of Invivyd is USD 52.55M

What is the 1 year trading range for Invivyd share price?

Invivyd has traded in the range of US$ 0.382 to US$ 5.195 during the past year

What is the PE ratio of Invivyd?

The price to earnings ratio of Invivyd is -2.79

What is the reporting currency for Invivyd?

Invivyd reports financial results in USD

What is the latest annual profit for Invivyd?

The latest annual profit of Invivyd is USD -198.64M

What is the registered address of Invivyd?

The registered address for Invivyd is CORPORATION TRUST CENTER, 1209 ORANGE ST, NEW CASTLE, WILMINGTON, DELAWARE, 19801

What is the Invivyd website address?

The website address for Invivyd is invivyd.com

Which industry sector does Invivyd operate in?

Invivyd operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

가장 활성
% 상승자
% 패자

기호	가격	볼륨
BTCTBTC Digital Ltd	US$ 8.2697 (73.73%)	61.45M
BDMDBaird Medical Investment Holdings Ltd	US$ 8.80 (62.36%)	18.63M
CRKNCrown Electrokinetics Corporation	US$ 0.1235 (54.96%)	764.86M
NUKKNukkleus Inc	US$ 29.97 (45.98%)	19.09M
GSITGSI Technology	US$ 3.97 (44.36%)	87.7M
DOGZDogness International Corporation	US$ 18.23 (-58.77%)	740.45k
ORKTOrangeKloud Technology Inc	US$ 3.02 (-24.88%)	21.08M
PMAXPowell Max Ltd	US$ 0.6364 (-23.31%)	4.17M
LGCBLinkage Global Inc	US$ 0.2876 (-22.27%)	890.66k
YYAIConnexa Sports Technologies Inc	US$ 0.8299 (-20.20%)	602.48k
CRKNCrown Electrokinetics Corporation	US$ 0.1235 (54.96%)	764.86M
GCTKGlucoTrack Inc	US$ 0.0852 (15.45%)	465.22M
RIMEAlgorhythm Holdings Inc	US$ 0.0406 (-4.02%)	387.23M
TGLTreasure Global Inc	US$ 0.2459 (14.75%)	267.1M
NVDANVIDIA Corporation	US$ 137.71 (3.10%)	201.4M